



California
Department of
Health Services

SANDRA SHEWRY
Director

State of California-Health and Human Services Agency
Department of Health Services



ARNOLD SCHWARZENEGGER
Governor

September 30, 2005

CHDP Provider Information Notice No.: 05-13

CORRECTED VERSION

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP)
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: ADDITION OF MENACTRA™, MENINGOCOCCAL CONJUGATE
VACCINE (MCV4), AS A CHDP BENEFIT, REPORTING CODES,
REIMBURSEMENT FOR VACCINE ADMINISTRATION, AND UPDATED
CHDP VACCINE BENEFIT AND REIMBURSEMENT TABLE

The purpose of this Provider Information Notice (PIN) is to inform you that the new Meningococcal Conjugate Vaccine (MCV4), Menactra™, has been added as a CHDP program benefit.

This Information Notice also provides background information on the vaccine, the new CHDP administration codes, and the provider reimbursement rates for vaccine administration. An updated CHDP vaccine benefit and reimbursement table is enclosed that includes the addition of this new meningococcal vaccine.

Background Information

Invasive meningococcal disease occurs in three common clinical forms: meningitis (49 percent of cases), blood infection (33 percent of cases), and pneumonia (9 percent of cases); other forms account for the remainder. Onset of disease can be abrupt and the course of the disease can be rapid. The case fatality rate is 10-14 percent (20 percent for adolescents); 11-19 percent of survivors suffer serious sequelae including deafness, neurologic deficit, or limb loss.

In January 2005, U.S. Food and Drug Administration (FDA) licensed a quadrivalent meningococcal conjugate vaccine (MCV4) for use in people from ages 11 to 55 years of age. Sanofi Pasteur Inc. is licensed by FDA to produce the newer MCV4 (Menactra™) and the existing meningococcal polysaccharide vaccine (MPSV4).

In comparison to polysaccharide vaccines, conjugate vaccines have proven to be extremely effective in providing sustained protection against *Haemophilus influenzae* type B and the pneumococcus. Since their introduction in 1999, monovalent Group C meningococcal conjugate vaccines have greatly reduced the incidence of Group C meningococcal disease in England. The incidence of meningococcal disease is highest during infancy with a secondary peak in fatal disease during late adolescence and early adulthood.

MCV4 is made of meningococcal capsular polysaccharide antigens conjugated to diphtheria toxoid protein. MCV4 prevents invasive meningococcal disease caused by four common serogroups of *Neisseria meningitidis*, A, C, Y and W-135. MCV4 offers no protection against meningococcal serogroup B, cause of most meningococcal cases during infancy and over 40 percent of all cases in California, or against diphtheria.

MCV4 is administered intramuscularly as a single 0.5-mL dose, preferably in the deltoid region and never in the buttocks. MCV4 can be administered concomitantly with other vaccines, but at a different anatomic site. Protective levels of antibodies are usually achieved within 7-10 days of vaccination.

The Advisory Committee on Immunization Practices (ACIP) expects that MCV4 will provide longer protection than MPSV4; however studies are needed to confirm this assumption. More data will become available in the next five years to guide recommendations on revaccination for persons who were previously vaccinated with MCV4.

ACIP and the American Academy of Pediatrics (AAP) currently recommend routine vaccination of young adolescents (11-12 years of age); adolescents at high school entry or 15 years of age (whichever comes first); all college freshmen living in dormitories; and other groups at high risk (military recruits, travelers to areas in which meningococcal disease is hyperendemic or epidemic, microbiologists who are routinely exposed to isolates of *N. meningitidis*, patients with anatomic or functional asplenia, and patients with terminal complement deficiency). These recommendations are in place until there is adequate supply of the vaccine to immunize everyone (11-55 years of age).

Meningococcal Conjugate Vaccine (MCV4) as a CHDP Program Benefit

Effective May 2, 2005, CHDP will reimburse providers for the administration fee of MCV4 to CHDP eligible children, 11 years through 18 years 11 months; the vaccine will be provided at no charge by the VFC Program for these children. The CHDP vaccine code is 69 and has the reimbursement rate of \$9.00 for the administration fee. MCV4 is available for purchase for CHDP eligible children, 19 years through 20 years 11 months. The total reimbursement rate is \$101.84, using both CHDP codes 70 and 73.

Meningococcal Conjugate Vaccine (MCV4)	69	VFC	11 years thru 18 years 11 months	\$ 9.00	
	70+73	Purchased	19 years thru 20 years 11 months	\$101.84	

These changes will be reflected in the Vaccine Codes and Rates table found in the rates max CHDP section of the CHDP Provider Manual.

Supplies of MCV4 are currently limited. Until you are informed that supplies are sufficient to vaccinate all 11-21 year olds, priority should be given to the following groups:

- Children and adolescents aged 11-21 years old who are:
 - Travelers to countries in which *N. meningitidis* is hyperendemic epidemic, particularly if contact with the local population will be prolonged;
 - Entering or current college freshmen who will reside in dormitories;
 - Persons with terminal complement deficiencies and those with anatomic or functional asplenia; or
 - Infected with HIV
- Children aged 11-12 years old at their preadolescent health assessment visit
- Adolescents at high-school entry (approximately 15 years old) who were not vaccinated at the preadolescent visit

Reminder:

All CHDP program providers actively involved with immunized children must participate in the VFC Program, which provides vaccines at no cost to the provider for eligible children up to eighteen years eleven months. The CHDP Program reimburses only the immunization administration fee for VFC covered vaccines.

Billing Instructions for VFC-covered MCV4

Please use the following instructions when billing for the administration of MCV4. Refer to the CHDP Provider Manual for additional information.

- Enter the CHDP Code number, 69, and MCV4 on a blank line, under the immunization section of the PM 160 Confidential Screening/Billing Report.
- Enter a check mark in only one of the Immunization Outcome Columns (A or B) of the PM 160, as appropriate.
- Enter the administration fee in the Fees Column (Note: fees do not apply on the "Information Only" PM 160).
- If you have administered MCV4 on or after May 2, 2005, and prior to this notice, you are entitled to reimbursement for the administration of this vaccine. Please submit a PM 160 for the \$9.00 administration fee if you have not been previously reimbursed for the vaccine by any source.

Billing Instructions for Purchased MCV4

- Enter each of the CHDP Code numbers (70 and 73) on separate lines of the PM 160 including the description of the vaccine (MCV4) for each line, under the immunization section of the PM 160 Confidential Screening/Billing Report.
- Enter a check mark for each billing code in only one of the Immunization Outcome Columns (A or B) of the PM 160, as appropriate.
- Enter \$99.99 in the Fees Column for code 70 and \$1.85 for code 73. (Note: fees do not apply on the "Information Only" PM 160).

CHDP Provider Information Notice No.: 05-13
Page 5
September 30, 2005

If you have administered MCV4 on or after May 2, 2005 and prior to this notice, you are entitled to reimbursement for the purchase of this vaccine if you have not been previously reimbursed for the vaccine by any source. Please submit a PM 160 for the purchase amount.

CHDP Vaccine Benefits and Reimbursement Table

An updated CHDP Vaccine Benefit and Reimbursement Table are enclosed; it is effective as of May 2, 2005. The table includes the MCV4 vaccine codes and reimbursement rates.

Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions about CHDP vaccine benefits or other CHDP issues, please contact your local CHDP Program office.

Original signed by Marian Dalsey, M.D., M.P.H.

Marian Dalsey, M.D., M.P.H., Acting Chief
Children's Medical Services Branch

Enclosure